All In Biotech

Drug Trial Radar · NCT05767047

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Mar 23, 2023

Primary completion

Mar 17, 2036

Study completion Mar 17, 2036

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.

Conditions

  • Behçet's Disease
  • Juvenile Psoriatic Arthritis

Interventions

  • ApremilastDrug

    Oral tablets or liquid suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Up to approximately 4 years
  2. Columbia-Suicide Severity rating Scale (C-SSRS)Time frame: Up to approximately 4 years
  3. Tanner StagingTime frame: Up to approximately 4 years
  4. Change from Baseline in Body WeightTime frame: Up to approximately 4 years
  5. Change from Baseline in HeightTime frame: Up to approximately 4 years
  6. Change from Baseline in Body Mass Index (BMI)Time frame: Up to approximately 4 years
  7. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to approximately 4 years
  8. Number of Participants with Clinically Significant Changes in Laboratory ParametersTime frame: Up to approximately 4 years

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • General Hospital of Thessaloniki Ippokrateio

    Thessaloniki, Greece · Recruiting

  • Meir Medical Center

    Kfar Saba, Israel · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, Valencia, Spain · Recruiting

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    Ankara, Turkey (Türkiye) · Recruiting

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi

    Istanbul, Turkey (Türkiye) · Recruiting

  • Umraniye Egitim ve Arastirma Hastanesi

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.